Explore tens of thousands of sets crafted by our community.
Biologics in Rheumatology
30
Flashcards
0/30
Infliximab
Mechanism: TNF inhibitor. Indications: Rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Certolizumab pegol
Mechanism: TNF inhibitor. Indications: Rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Belimumab
Mechanism: B-lymphocyte stimulator (BLyS)-specific inhibitor. Indications: Systemic lupus erythematosus.
Canakinumab
Mechanism: IL-1β inhibitor. Indications: Cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease.
Ixekizumab
Mechanism: IL-17A inhibitor. Indications: Psoriatic arthritis, plaque psoriasis.
Baricitinib
Mechanism: JAK1 and JAK2 inhibitor. Indications: Rheumatoid arthritis.
Brodalumab
Mechanism: IL-17 receptor antagonist. Indications: Plaque psoriasis.
Tildrakizumab
Mechanism: IL-23 inhibitor. Indications: Plaque psoriasis.
Tocilizumab
Mechanism: IL-6 receptor antagonist. Indications: Rheumatoid arthritis, giant cell arteritis, cytokine release syndrome.
Rituximab
Mechanism: CD20-directed cytolytic antibody. Indications: Rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis.
Tofacitinib
Mechanism: Janus kinase (JAK) inhibitor. Indications: Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis.
Dupilumab
Mechanism: IL-4 and IL-13 antagonist. Indications: Moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps.
Apremilast
Mechanism: PDE4 inhibitor. Indications: Psoriatic arthritis, plaque psoriasis, oral ulcers associated with Behçet's disease.
Guselkumab
Mechanism: IL-23 inhibitor. Indications: Psoriatic arthritis, plaque psoriasis.
Golimumab
Mechanism: TNF inhibitor. Indications: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
Secukinumab
Mechanism: IL-17A inhibitor. Indications: Psoriatic arthritis, ankylosing spondylitis, plaque psoriasis.
Reslizumab
Mechanism: IL-5 antagonist. Indications: Severe eosinophilic asthma.
Ustekinumab
Mechanism: IL-12 and IL-23 inhibitor. Indications: Psoriatic arthritis, plaque psoriasis, Crohn's disease.
Upadacitinib
Mechanism: JAK1 inhibitor. Indications: Rheumatoid arthritis, psoriatic arthritis.
Omalizumab
Mechanism: IgE inhibitor. Indications: Moderate to severe persistent allergic asthma, chronic idiopathic urticaria.
Adalimumab
Mechanism: TNF inhibitor. Indications: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis.
Mepolizumab
Mechanism: IL-5 antagonist. Indications: Severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis.
Fremanezumab
Mechanism: CGRP antagonist. Indications: Migraine prevention.
Abatacept
Mechanism: Selective T-cell costimulation modulator. Indications: Rheumatoid arthritis, juvenile idiopathic arthritis.
Benralizumab
Mechanism: IL-5 receptor antagonist. Indications: Severe eosinophilic asthma.
Etanercept
Mechanism: TNF inhibitor. Indications: Rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Sarilumab
Mechanism: IL-6 receptor antagonist. Indications: Rheumatoid arthritis.
Filgotinib
Mechanism: JAK1 inhibitor. Indications: Rheumatoid arthritis.
Anakinra
Mechanism: IL-1 receptor antagonist. Indications: Rheumatoid arthritis, cryopyrin-associated periodic syndromes, neonatal-onset multisystem inflammatory disease.
Risankizumab
Mechanism: IL-23 inhibitor. Indications: Psoriatic arthritis, plaque psoriasis.
© Hypatia.Tech. 2024 All rights reserved.
